Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 9/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 9/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19105005 | 0.96 | TAS1R3 (0.38) | TAS1R3TAS1R1TAS1R2ELANEGAA | |
| SCHEMBL26144738 | 0.92 | ELANE (0.36) | TAS1R3TAS1R1TAS1R2ELANEGAA | |
| SCHEMBL26144727 | 0.90 | ELANE (0.35) | TAS1R3TAS1R1TAS1R2ELANEGAA | |
| SCHEMBL11915792 | 0.89 | ELANE (0.42) | ELANEGAAALOX15 | |
| SCHEMBL12213944 | 0.77 | MAPT (0.42) | ELANEGAAALOX15MAPT | |
| SCHEMBL23228270 | 0.76 | FABP3 (0.35) | ELANE | |
| SCHEMBL26316856 | 0.76 | ELANE (0.34) | ELANE | |
| SCHEMBL16838219 | 0.76 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL22381449 | 0.75 | GAA (0.37) | ELANEGAAALOX15F10 | |
| SCHEMBL19105004 | 0.75 | ELANE (0.37) | ELANEGAAALOX15L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036078-B2 | Oral products and methods for producing the same | PolySpectra, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230399515-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | Rakuten Medical, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11802279-B2 | Modified L-asparaginase | JAZZ PHARMACEUTICALS IRELAND LTD. (IE) | 2023-10-31 | — | — | US | disclosed |
| US-11788133-B2 | Methods and compositions for sequencing complementary polynucleotides | Singular Genomics Systems, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230293701-A1 | LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF | ARGORNA PHARMACEUTICALS CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-11725077-B2 | Olefin metathesis photopolymers | PolySpectra, Inc. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11697736-B2 | Silicon containing detectable compounds | Singular Genomics Systems, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230193377-A1 | METHODS AND COMPOSITIONS FOR SEQUENCING COMPLEMENTARY POLYNUCLEOTIDES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-22 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20160121002-A1 | Bioorthogonal Turn-on Probes | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-05 | — | — | US | disclosed |
| US-20150175998-A1 | Methods and Kits to Create Protein Substrate˜HECT-Ubiquitin Ligase Pairs | NORTHWESTERN UNIVERSITY | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697736-B2 | Silicon containing detectable compounds | AS3MT, SCLY, NASP | TAS1R3 3183/4885TAS1R1 3315/4885TAS1R2 3642/4885 |
| US-11802279-B2 | Modified L-asparaginase | DNPEP, LNPEP, ANPEP | TAS1R3 4703/4885TAS1R1 4681/4885TAS1R2 4698/4885 |
| US-20160121002-A1 | Bioorthogonal Turn-on Probes | MPI, TIPRL, BAZ1A | TAS1R3 4086/4885TAS1R1 3298/4885TAS1R2 3803/4885 |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | TAS1R3 2981/4885TAS1R1 2921/4885TAS1R2 2835/4885 |
| US-12036078-B2 | Oral products and methods for producing the same | CROCC, RPAP1, RUVBL1 | TAS1R3 3710/4885TAS1R1 3637/4885TAS1R2 3588/4885 |
| US-20230293701-A1 | LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF | ASGR1, HAVCR2, SLC10A1 | TAS1R3 2609/4885TAS1R1 2512/4885TAS1R2 2407/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | TAS1R3 3208/4885TAS1R1 3231/4885TAS1R2 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.